JACC This Week

In this episode, Dr. Valentin Fuster highlights key research from the March 18th, 2025 issue of the JACC. The studies cover groundbreaking findings in heart failure management, genetic testing in cardiovascular diseases, the effectiveness of a new drug for amyloidosis, and the cardiovascular harm caused by smoking, offering valuable insights for clinical practice and patient care.

In this episode, Dr. Valentin Fuster dives into a groundbreaking scientific statement from the American Heart Association and American College of Cardiology, providing updated clinical considerations for competitive athletes with cardiovascular abnormalities. The statement, which integrates 40 years of research, focuses on preventing sudden cardiac death and improving shared decision-making strategies for athletes facing heart conditions, offering expert guidance across 11 key task forces.

In this podcast highlights the growing concern over transcatheter valve failure following transcatheter aortic valve replacement (TAVR), emphasizing the need for standardized imaging protocols and frequent follow-ups. Experts discuss best practices for monitoring and managing these patients, urging collaborative international efforts to validate new imaging techniques and improve patient outcomes.

In this episode, Dr. Valentin Fuster discusses a groundbreaking study on the link between cigarette smoking and subclinical cardiovascular harm, focusing on markers of inflammation, thrombosis, and atherosclerosis. The research, based on data from over 182,000 participants across 22 cohorts, reveals how smoking intensity and duration impact early cardiovascular damage and highlights the potential of these biomarkers in shaping future public health strategies and regulatory policies.

In this episode, Dr. Valentin Fuster highlights a groundbreaking study on acoramides, a novel treatment for transthyretin amyloid cardiomyopathy (ATTR), which shows significant reductions in mortality and cardiovascular hospitalizations compared to a placebo. Experts discuss the clinical implications, comparing acoramides to the previously approved tafamidis, noting exciting advancements in treatments for a once-untreatable disease.

In this episode, Dr. Valentin Fuster discusses a 14-year study on the clinical impact of genetic testing for inherited cardiovascular diseases, conducted by Dr. Steffany Grondin at the Montreal Heart Institute. The study found that genetic testing helped diagnose 24% of patients, refine clinical management, and improve variant interpretation, while also highlighting the need for more research and better access to genetic expertise in healthcare.

In this week's JACC Baran (Episode 4), hosts Mitsuaki Sawano, MD, JACC Executive Associate Editor, and Shun Kohsaka, MD, FACC, JACC Regional Editor welcome Koshiro Sakai, MD, to discuss the 2025 revised ACS guidelines and Photon-Counting CT (PCD-CT). A retrospective cohort study of 7,500 cases suggested an association between PCD-CT and enhanced diagnostic accuracy, with potential implications for reducing unnecessary invasive catheterization procedures. The episode also highlights global research perspectives and the importance of clear scientific communication.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.

The field of transcatheter aortic valve replacement (TAVR) continues to evolve, with new research expanding its indications and refining its application. This JACC special issue brings together cutting-edge studies, meta-analyses, and expert perspectives on key topics shaping the future of TAVR. Highlights include pivotal trials assessing TAVR in low-risk patients, a growing focus on moderate aortic stenosis and heart failure, and novel insights into reintervention strategies. The issue also presents comprehensive analyses on asymptomatic severe aortic stenosis, valve durability, and patient selection for next-generation TAVR applications. As TAVR increasingly moves beyond its initial role in high-risk patients, the studies featured here provide essential data to guide clinical decision-making, optimize outcomes, and address the challenges of valve longevity, structural durability, and patient-centric approaches. We hope this collection informs and inspires continued innovation in structural heart disease management.

In this episode, Dr. Valentin Fuster summarizes the March 11, 2025 issue of the JACC, which features groundbreaking research on transcatheter aortic valve replacement (TAVR) and its expanding applications. The podcast delves into the latest studies on TAVR's impact on heart failure patients, the need for better patient selection, and how new findings are shaping the future of aortic stenosis treatment.